How to Interpret Recent CV Outcome Trials and Future: PCSK9 Inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

How to Interpret Recent CV Outcome Trials and Future: PCSK9 Inhibitors

Published:2018 Issue:1 Volume:7 Page:1
ISSN:2287-2892
Container-title:Journal of Lipid and Atherosclerosis
language:en
Short-container-title:J Lipid Atheroscler

Author:

Lee Eun Young¹,Yoon Kun-Ho¹²

Affiliation:

1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

2. Institute of Catholic Ubiquitous Health Care, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Publisher

Korean Society of Lipidology and Atherosclerosis

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://synapse.koreamed.org/pdf/10.12997/jla.2018.7.1.1

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reduction of Cardiovascular Risk Using Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Acute Coronary Syndrome: A Systematic Review;Cureus;2023-02-05

2. Meta‐analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes;ESC Heart Failure;2022-11-07

3. Management of High-Risk Hypercholesterolemic Patients and PCSK9 Inhibitors Reimbursement Policies: Data from a Cohort of Italian Hypercholesterolemic Outpatients;Journal of Clinical Medicine;2022-08-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP